Bryan, Garnier & Co announces the filing of European Biotech Galapagos for a Nasdaq IPO.
April 17th, 2015 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces that Galapagos filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed global offering of ordinary shares, including ordinary shares in the form of American Depositary Shares ("ADSs"). Bryan, Garnier & Co is the sole European investment bank in the European biotech Galapagos contemplated NASDAQ IPO syndicate, alongside Morgan Stanley, Credit Suisse, Cowen and Nomura.
Galapagos' ordinary shares are currently listed on Euronext
Amsterdam and Euronext Brussels. Application has been made to list the
ADSs to be offered in the global offering on the NASDAQ Stock Market in the
United States under the symbol "GLPG." Within the framework of the
contemplated transaction, Galapagos expects to offer ordinary shares in Europe
and countries outside of the United States and Canada in a concurrent private
The registration statement contains a proposed maximum aggregate
offering price of $150m.
Morgan Stanley, Credit Suisse, and Cowen and Company are acting
as joint book-running managers, and Nomura and Bryan, Garnier & Co are
acting as co-managers, for the proposed global offering.
About Galapagos ( www.glpg.com)
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is an international growth focused
independent investment bank with operations in London, Paris, Geneva, New York
and New Delhi. Since 1996, Bryan, Garnier & Co has dealt with over 300
corporate clients. The firm employs 120 people and provides equity research,
sales & trading, private and public capital raising and M&A services to
growth companies and their investors, with a focus on the TMT, Healthcare,
Renewable Energies & Environment, Specialty Retail and Business Services
industry sectors. In 2013, Bryan, Garnier & Co received the Most Productive
European Broker Award by Financial Times / Starmine.
Bryan, Garnier & Co is a fully registered broker dealer authorized by the FCA in Europe and by the FINRA in the USA, and is a member of the London Stock Exchange, a member of NYSE Euronext and a listing sponsor on Alternext.